Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
MetadataShow full item record
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
Version of record
Small cell lung cancer
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Cell Transformation, Neoplastic
Drug Resistance, Neoplasm
Positron Emission Tomography Computed Tomography
Small Cell Lung Carcinoma
License start date
Lung Cancer, 2017, 111 pp. 65 - 68
Showing items related by title, author, creator and subject.
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. Li, H; Stokes, W; Chater, E; Roy, R; de Bruin, E; Hu, Y; Liu, Z; Smit, EF; Heynen, GJ; Downward, J; Seckl, MJ; Wang, Y; Tang, H; Pardo, OE (2016)Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through ...
Ali, A; Mohamed, M; Chisholm, J; Thway, K (2016-07-18)Desmoplastic small round cell tumor (DSRCT) is an aggressive small round cell sarcoma that typically occurs intra-abdominally in adolescents and young adults, and is characterized by a recurrent t(11;22)(p13;q12) translocation ...